Palvella Therapeutics, Inc (PVLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.23B
Last updated: Nov 17, 2026 at 11:05 AM ET
Palvella Therapeutics, Inc (PVLA) Earnings: Report Dates and Results
Palvella Therapeutics (PVLA) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Palvella Therapeutics reported EPS of -$1.70, below the -$1.65 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PVLA has an expected report date of Mar 29, 2027.
PVLA Earnings Call
The latest PVLA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 9 quarters below that had an estimate, PVLA beat 1 and missed 8. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 798.74% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.70 | -$1.65 | -$2.31 - -$1.05 | -3.03% | Miss | N/A | 13 | 0 up, 1 down | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$1.52 | -$1.16 | -$1.42 - -$0.86 | -31.03% | Miss | N/A | 12 | 2 up, 6 down | Aug 4, 2026 | N/A |
| Mar 31, 2026 | -$1.20 | -$0.93 | -$1.15 - -$0.77 | -29.03% | Miss | N/A | 11 | 3 up, 4 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$1.08 | -$0.91 | -$1.06 - -$0.30 | -18.58% | Miss | N/A | 13 | 2 up, 0 down | Mar 31, 2026 | N/A |
| Sep 30, 2025 | -$1.03 | -$0.85 | -$0.99 - -$0.63 | -21.18% | Miss | N/A | 11 | 2 up, 4 down | Nov 11, 2025 | N/A |
| Jun 30, 2025 | -$0.86 | -$0.77 | N/A | -11.69% | Miss | N/A | N/A | N/A | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.74 | -$3.40 | N/A | +78.24% | Beat | N/A | 3 | 0 up, 0 down | May 15, 2025 | N/A |
| Dec 31, 2024 | -$5.37 | -$0.60 | -$0.70 - -$0.39 | -798.74% | Miss | N/A | 3 | 0 up, 0 down | Mar 31, 2025 | N/A |
| Sep 30, 2024 | -$2.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$2.76 | -$0.03 | N/A | N/A | N/A | -169.1% | N/A | N/A | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$3.95 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2024 | $53000 |
| Dec 31, 2023 | -$3.71 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 29, 2024 | $1.30M |
| Sep 30, 2023 | -$8.70 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2023 | $19.52M |
| Jun 30, 2023 | $4.00 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2023 | $20.05M |
| Mar 31, 2023 | -$14.40 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | May 10, 2023 | $1.94M |
| Dec 31, 2022 | -$8.80 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 29, 2023 | $5.85M |
| Sep 30, 2022 | -$10.40 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 2, 2022 | $5.37M |
| Jun 30, 2022 | -$11.20 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 4, 2022 | $3.70M |
| Mar 31, 2022 | -$5.60 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2022 | $10.99M |
| Dec 31, 2021 | -$12.00 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 1, 2022 | $8.44M |
| Sep 30, 2021 | -$19.20 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 2, 2021 | $4.06M |
| Jun 30, 2021 | -$20.00 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 4, 2021 | $3.29M |
| Mar 31, 2021 | -$5.60 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | May 17, 2021 | $15.63M |
| Dec 31, 2020 | -$20.80 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | $1.88M |
| Sep 30, 2020 | -$20.80 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 4, 2020 | $2.94M |
| Jun 30, 2020 | -$7.20 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2020 | $11.25M |
| Mar 31, 2020 | -$5.60 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2020 | $13.26M |
| Dec 31, 2019 | -$4.80 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 12, 2020 | $17.27M |
| Sep 30, 2019 | -$4.00 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 11, 2019 | $15.13M |
| Jun 30, 2019 | -$19.20 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 7, 2019 | $5.33M |
| Mar 31, 2019 | -$16.00 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2019 | $8.54M |
| Dec 31, 2018 | -$17.60 | -$0.18 | N/A | N/A | N/A | -222.2% | N/A | N/A | Mar 20, 2019 | $4.91M |
| Sep 30, 2018 | -$8.80 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2018 | $8.35M |
| Jun 30, 2018 | -$0.30 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2018 | $11.69M |
| Mar 31, 2018 | -$0.17 | -$0.02 | N/A | -750.00% | Miss | N/A | N/A | N/A | May 10, 2018 | $4.15M |
| Dec 31, 2017 | $14.40 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 9, 2018 | $18.15M |
| Sep 30, 2017 | -$12.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2017 | $3.93M |
| Jun 30, 2017 | -$18.59 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2017 | $1.85M |
| Mar 31, 2017 | -$14.85 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2017 | $1.34M |
| Dec 31, 2016 | -$12.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 23, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.71, after -$14.28 the year before. It was -$43.57 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.71 | N/A |
| Dec 31, 2024 | -$14.28 | N/A |
| Dec 31, 2023 | -$22.81 | N/A |
| Dec 31, 2022 | -$36.00 | N/A |
| Dec 31, 2021 | -$56.80 | N/A |
| Dec 31, 2020 | -$54.40 | N/A |
| Dec 31, 2019 | -$44.00 | N/A |
| Dec 31, 2018 | -$26.87 | N/A |
| Dec 31, 2017 | -$31.76 | N/A |
| Dec 31, 2016 | -$43.57 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,510 | 11 | |
| 2026Q2 | Jun 30, 2026 | 8,260 | 13 |
2026Q3 Earnings Call
Opening remarks
Bohan Wei Vice President of Corporate Development and New Product Planning Thank you, operator. Good morning, and thank you for joining Palvella Therapeutics' Third Quarter 2026 financial results and corporate update call. As a reminder, our press release detailing today's announcements can be found in the Investors section of our website at www.palvellatx.com. On today's call, you will first hear from Wesley H. Kaupinen, our founder and executive officer, followed by Ashley Kline, our chief commercial officer, Dr. Jeff Martini, our chief scientific officer, and Matthew E. Korenberg, our chief financial officer. Before we begin, please note that today's remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning, and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. And now, I will turn the call over to Wesley.
Wesley H. Kaupinen Founder and Executive Officer Thanks, Bohan. Good morning, everyone, and thank you all for joining us on Palvella Therapeutics' Third Quarter earnings call and corporate update. For children and adults living with microcystic lymphatic malformations, every day counts. Microcystic lymphatic malformations are a serious, rare, and chronically debilitating genetic disease. Starting at a young age, daily life can be impacted by persistent leaking and bleeding from lymphatic lesions, functional impairment, infections, disfigurement, and the physical and psychological burden of living with a lifelong infiltrative disease that progressively worsens over time. Despite this profound burden of disease, there are currently no FDA-approved therapies for microcystic lymphatic malformations. Last Wednesday, October 28, a major milestone was achieved that could soon change the treatment paradigm for individuals living with microcystic lymphatic malformations. Our team at Palvella Therapeutics announced that the FDA has accepted our new drug application for QTORIN rapamycin for the treatment of microcystic LMs, and furthermore, that the program has been granted the FDA's priority review designation. This designation is for medicines that, if approved, would offer significant improvements in the safety or effectiveness of treating serious conditions, and it sets a six-month FDA review goal rather than the standard 10-month review. In light of this milestone, I want to take a moment to recognize the patients and families who have participated in our clinical studies, our clinical investigators, our patient advocacy collaborators, our highly dedicated employees, and everyone who helped us reach this important point. Thank you. Furthermore, 116 days from today, on February 28, 2027, the Palvella team, working in conjunction with our physician and patient advocacy collaborators, will have the potential opportunity to begin transforming the lives of these patients through the commercialization of QTORIN rapamycin, if approved. Our goal is not simply to bring another medicine to market.
Frequently Asked Questions About PVLA
When is Palvella Therapeutics's next earnings date?
Palvella Therapeutics's next earnings report is expected for Mar 29, 2027.
Did PVLA beat earnings estimates last quarter?
No. Palvella Therapeutics reported EPS of -$1.70 for the quarter ended Sep 30, 2026, below the -$1.65 estimate by 3.03%.
What EPS do analysts expect from PVLA next quarter?
The consensus EPS estimate for Palvella Therapeutics for the quarter ending Dec 31, 2026 is -$2.15 from 17 analysts, with estimates from -$2.68 to -$1.72.
How often does PVLA beat earnings estimates?
Palvella Therapeutics beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -104.38%.
PVLA pages: Overview, Earnings, Forecast, Financials, Competitors